VOL 1 | ISSUE 1

Follicular Lymphoma™ UPDATE

Conversations with Oncology Investigators
Bridging the Gap between Research and Patient Care

FACULTY INTERVIEWS

Nathan H Fowler, MD

Gilles A Salles, MD, PhD

EDITOR

Neil Love, MD

ABIM CME MOC ACCREDITED

CME Certified

Follicular Lymphoma™
UPDATE

Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com
For CME/CNE Information	Email: CE@ResearchToPractice.com

Follicular Lymphoma Update
A Continuing Medical Education Audio Series

OVERVIEW OF ACTIVITY

Follicular lymphoma (FL) is an indolent form of non-Hodgkin lymphoma that can vary significantly in its clinical presentation. Because of this variety, no single standard approach to the initial management of the disease has been established and available options range from watchful waiting, radiation therapy and rituximab monotherapy to various combinations of chemoimmunotherapy. Recent data sets and corresponding FDA actions have led to the emergence of new therapeutic targets and regimens, thereby altering management algorithms, and in order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES

- Evaluate emerging research data and recent FDA approvals when designing an optimal therapeutic approach for patients with newly diagnosed FL requiring active therapy.
- Recall published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory (R/R) FL.
- Compare and contrast the efficacy and safety of the PI3-kinase inhibitors approved for the treatment of R/R FL to determine the current role of each in clinical practice.
- Develop practical strategies to prevent, recognize and ameliorate the toxicities associated with therapies routinely used in the management of FL.
- Identify ongoing clinical trials evaluating innovative investigational approaches for FL, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide *aggregate* and *deidentified* data to third parties, including commercial supporters. **We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.**

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio tracks, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at **ResearchToPractice.com/FLUpdate119/CME**. The corresponding video program is available as an alternative at **ResearchToPractice.com/FLUpdate119/Video**.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation and Gilead Sciences Inc.

Release date: February 2019; Expiration date: February 2020

CME INFORMATION

FACULTY AFFILIATIONS

Nathan H Fowler, MD
Director of Clinical Investigation
and Translational Research
Lead, Phase I and Indolent
Research Groups
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Gilles A Salles, MD, PhD
Professor of Medicine
Université Claude Bernard
Head of the Hematology Department
Hospices Civils de Lyon
Lyon, France

EDITOR

Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Fowler** — Advisory Committee: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, Roche Laboratories Inc, TG Therapeutics Inc. **Dr Salles** — Advisory Committee: AbbVie Inc, Celgene Corporation, Novartis, Roche Laboratories Inc; Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Merck, MorphoSys, Novartis, Roche Laboratories Inc, Servier, Takeda Oncology; Contracted Research: Celgene Corporation, Roche Laboratories Inc.

EDITOR — **Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

If you would like to discontinue your complimentary subscription to *Follicular Lymphoma Update*, please email us at **Info@ResearchToPractice.com**, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Interview with Nathan H Fowler, MD

Tracks 1-26

Track 1 Overview of current treatment approaches in follicular lymphoma (FL)

Track 2 Mechanism of action of the anti-CD20 antibodies rituximab and obinutuzumab

Track 3 Activity of lenalidomide and possible correlation of cereblon expression with response in FL

Track 4 Inhibition of the PI3-kinase pathway in low-grade lymphomas

Track 5 Activity of BTK inhibitors in FL

Track 6 Rationale for the Phase III RELEVANCE trial: Lenalidomide/rituximab (R^2) versus rituximab/chemotherapy, each followed by maintenance rituximab, as first-line therapy for FL

Track 7 Design of the RELEVANCE study for patients with previously untreated FL

Track 8 Duration of up-front R^2 and maintenance rituximab

Track 9 Adherence to long-term lenalidomide therapy

Track 10 Perspective on the 3-year progression-free survival results from the RELEVANCE trial

Track 11 Tolerability of R^2 versus rituximab/chemotherapy

Track 12 Clinical experience with lenalidomide-associated neutropenia, rash and diarrhea

Track 13 Second-line therapy options for patients who receive first-line R^2

Track 14 **Case:** A 52-year-old woman with symptomatic Grade I/II FL attains a complete remission (CR) with first-line R^2 therapy

Track 15 **Case:** A 53-year-old woman who previously received several lines of therapy, including R-CHOP, BR, R^2 and idelalisib, receives chimeric antigen receptor (CAR) T-cell therapy on a clinical trial

Track 16 Activity of CAR T-cell therapies in FL

Track 17 Potential synergy of lenalidomide and CAR T-cell therapy

Track 18 Activity of idelalisib for patients with FL

Track 19 Side effects and quality of life with idelalisib

Track 20 **Case:** A 73-year-old woman with relapsed/refractory FL receives copanlisib

Track 21 Selection of PI3-kinase inhibitor for patients with FL

Track 22 Risks and benefits with idelalisib versus copanlisib

Track 23 Treatment options for patients with FL and early disease relapse

Track 24 **Case:** A 43-year-old man presents with Grade IIIA FL, receives R-CHOP and experiences a CR lasting for 5 years

Track 25 Response to second-line lenalidomide/obinutuzumab

Track 26 Perspective on the use of CAR T-cell therapy or immune checkpoint inhibition for patients with transformed FL

Interview with Gilles A Salles, MD, PhD

Tracks 1-20

Track 1 **Case:** A 56-year-old man with Stage IV FL achieves a CR with the R^2 regimen as first-line therapy on a clinical trial

Track 2 Therapeutic approach to Grade III FL

Track 3 Deciding between treatment and observation for patients with newly diagnosed FL

Track 4 RELEVANCE: A Phase III trial evaluating R^2 versus rituximab/chemotherapy, each followed by maintenance rituximab, for previously untreated FL

Track 5 Dosing and administration schedule of the R^2 regimen

Track 6 Side effects and quality of life with R^2 versus rituximab/chemotherapy

Track 7 Activity and tolerability of R^2 in patients with untreated FL

Interview with Dr Salles (continued)

Track 8	**Case:** A 78-year-old woman who receives idelalisib for relapsed FL experiences gastrointestinal and hepatic toxicity
Track 9	Efficacy and tolerability of idelalisib
Track 10	Monitoring and management of hepatic toxicity and neutropenia associated with idelalisib
Track 11	Risk of opportunistic infections and colitis with idelalisib
Track 12	Comparison of the PI3-kinase isoforms targeted and the tolerability of idelalisib, duvelisib and copanlisib
Track 13	Perspective on the differences in efficacy among PI3-kinase inhibitors
Track 14	Hyperglycemia associated with copanlisib
Track 15	Therapeutic options for patients with relapsed FL
Track 16	Approach to patients with FL who experience relapse early in their treatment course
Track 17	Perspective on the efficacy of obinutuzumab-based chemotherapy versus rituximab-based chemotherapy for FL
Track 18	**Case:** A 44-year-old man receives rituximab for Stage II FL and experiences disease transformation to diffuse large B-cell lymphoma
Track 19	Efficacy of CAR T-cell therapy for patients with FL
Track 20	**Case:** A 55-year-old man experiences a prolonged CR after receiving rituximab for relapsed FL

Video Program

View the corresponding video interviews with (from left) Drs Fowler and Salles by Dr Love at www.ResearchToPractice.com/FLUpdate119/Video

Have Questions or Cases You Would Like Us to Pose to the Faculty?

Submit them to us via Facebook or Twitter and we will do our best to get them answered for you

Facebook.com/ResearchToPractice or Twitter @DrNeilLove

SELECT PUBLICATIONS

Armitage JO, Longo DL. **Which anti-CD20 antibody is better in follicular lymphoma?** *N Engl J Med* 2017;377(14):1389-90.

Bartlett NL et al. **Single-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial.** *Blood* 2018;131(2):182-90.

Cheah CY, Fowler NH. **Novel agents for relapsed and refractory follicular lymphoma.** *Best Pract Res Clin Haematol* 2018;31(1):41-8.

Cheson BD et al. **Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study.** *J Clin Oncol* 2018;36(22):2259-66.

Dreyling M et al. **Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma.** *J Clin Oncol* 2017;35(35):3898-905.

Fowler NH et al. **Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).** *Proc ASCO* 2018;**Abstract 7549**.

Fowler NH et al. **A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE).** *Proc ASCO* 2017;**Abstract TPS7576**.

Fowler NH et al. **Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.** *Proc ASCO* 2017;**Abstract 7531**.

Gopal AK et al. **Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study.** *J Clin Oncol* 2018;36(23):2405-12.

Gopal AK et al. **Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.** *Blood* 2017;129(22):3037-9.

Hiddemann W et al. **Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety.** *J Clin Oncol* 2018;36(23):2395-404.

Ito T, Handa H. **Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.** *Int J Hematol* 2016;104(3):293-9.

Marcus R et al. **Obinutuzumab for the first-line treatment of follicular lymphoma.** *N Engl J Med* 2017;377(14):1331-44.

Morschhauser F et al. **An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.** *Blood* 2018;132(14):1486-94.

Morschhauser F et al; RELEVANCE trial investigators. **Rituximab plus lenalidomide in advanced untreated follicular lymphoma.** *N Engl J Med* 2018;379(10):934-47.

Nastoupil L et al. **High complete response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Results of an open-label, phase II study.** *Proc ASH* 2017;**Abstract 414**.

Schuster SJ et al. **Chimeric antigen receptor T cells in refractory B-cell lymphomas.** *N Engl J Med* 2017;377(26):2545-54.

Sehn LH et al. **Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.** *Proc ASCO* 2018;**Abstract 7507**.

Smith SM et al. **Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.** *Lancet Haematol* 2017;4(4):e176-82.

Strati P et al. **Long-term remissions of patients with follicular lymphoma grade 3 treated with R-CHOP.** *Clin Lymphoma Myeloma Leuk* 2018;18(1):e103-8.

Tilly H et al; Lymphoma Study Association. **Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: A single-arm, open-label, phase 2 study.** *Lancet Haematol* 2018;5(9):e403-10.

Tran E et al. **A milestone for CAR T cells.** *N Engl J Med* 2017;377(26):2593-6.

Younes A et al. **Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: An interim analysis.** *Proc ASH* 2017;**Abstract 481**.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. **Idelalisib may be associated with an increased risk for _____.**
   a. Neutropenia
   b. Colitis
   c. Hepatotoxicity
   d. Opportunistic infections
   e. All of the above

2. **Which of the following statements is true regarding the Phase III RELEVANCE study comparing R^2 to rituximab/chemotherapy, each followed by maintenance rituximab, for previously untreated FL?**
   a. R^2 significantly improved progression-free survival
   b. R^2 significantly improved the CR rate
   c. R^2 and rituximab/chemotherapy demonstrated similar efficacy

3. **The phase III GALLIUM study comparing first-line obinutuzumab-based chemotherapy to rituximab-based chemotherapy, followed by obinutuzumab or rituximab maintenance, demonstrated no difference in progression-free survival.**
   a. True
   b. False

4. **A recent study by Schuster and colleagues published in *The New England Journal of Medicine* evaluating the efficacy of CAR T-cell therapy in patients with refractory diffuse large B-cell lymphoma or FL reported a CR rate of approximately _____ in the FL cohort.**
   a. 30%
   b. 50%
   c. 70%

5. **The ongoing AUGMENT trial is evaluating the R^2 regimen versus rituximab alone for patients with indolent non-Hodgkin lymphoma in which setting?**
   a. First line
   b. Relapsed/refractory disease

6. **Side effects associated with lenalidomide include _____.**
   a. Neutropenia
   b. Constipation
   c. Diarrhea
   d. All of the above
   e. Both a and c

7. **What is the mechanism of action of tazemetostat, an agent that has shown promising response rates in the treatment of relapsed/refractory FL?**
   a. Immune checkpoint inhibitor
   b. Antibody-drug conjugate
   c. EZH2 inhibitor

8. **In the RELEVANCE trial, the toxicity profile of the R^2 regimen was observed to be similar to that of rituximab/chemotherapy, with similar rates of neutropenia, diarrhea and alopecia.**
   a. True
   b. False

9. **Which statement is true regarding copanlisib in the treatment of FL?**
   a. It is administered orally
   b. It inhibits the alpha and delta isoforms of PI3 kinase
   c. It may be associated with hyperglycemia and hypertension
   d. All of the above
   e. Both a and b
   f. Both b and c

10. **What was the duration of maintenance therapy with rituximab in both the PRIMA and RELEVANCE trials?**
    a. 12 months
    b. 18 months
    c. 24 months

EDUCATIONAL ASSESSMENT AND CREDIT FORM

Follicular Lymphoma Update — Volume 1, Issue 1

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Results and clinical implications of the RELEVANCE study of R^2 for patients with previously untreated FL	4 3 2 1	4 3 2 1
Efficacy and side effects of PI3-kinase inhibitors for patients with FL	4 3 2 1	4 3 2 1
Activity and tolerability of the R^2 regimen for patients with FL	4 3 2 1	4 3 2 1
Emerging data with CAR T-cell therapies in FL	4 3 2 1	4 3 2 1
Efficacy of obinutuzumab-based chemotherapy versus rituximab-based chemotherapy in FL	4 3 2 1	4 3 2 1

Practice Setting:

☐ Academic center/medical school ☐ Community cancer center/hospital ☐ Group practice

☐ Solo practice ☐ Government (eg, VA) ☐ Other (please specify).....

Approximately how many new patients with FL do you see per year? ..... patients

Was the activity evidence based, fair, balanced and free from commercial bias?

☐ Yes ☐ No If no, please explain: .....

.....

Please identify how you will change your practice as a result of completing this activity (select all that apply).

☐ This activity validated my current practice
☐ Create/revise protocols, policies and/or procedures
☐ Change the management and/or treatment of my patients
☐ Other (please explain): .....

If you intend to implement any changes in your practice, please provide 1 or more examples:

.....

.....

.....

The content of this activity matched my current (or potential) scope of practice.

☐ Yes ☐ No If no, please explain: .....

.....

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Evaluate emerging research data and recent FDA approvals when designing an optimal therapeutic approach for patients with newly diagnosed FL requiring active therapy. ..... 4 3 2 1 N/M N/A
- Recall published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory (R/R) FL. ..... 4 3 2 1 N/M N/A
- Compare and contrast the efficacy and safety of the PI3-kinase inhibitors approved for the treatment of R/R FL to determine the current role of each in clinical practice. ..... 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

As a result of this activity, I will be able to:

- Develop practical strategies to prevent, recognize and ameliorate the toxicities associated with therapies routinely used in the management of FL. . . . . 4 3 2 1 N/M N/A
- Identify ongoing clinical trials evaluating innovative investigational approaches for FL, and obtain consent from appropriate patients for study participation.. . . . . 4 3 2 1 N/M N/A

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

. . . . . .

. . . . . .

Would you recommend this activity to a colleague?

☐ Yes ☐ No

If no, please explain: . . . . . .

PART 2 — Please tell us about the faculty and editor for this educational activity

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

Faculty	**Knowledge of subject matter**	**Effectiveness as an educator**
Nathan H Fowler, MD	4 3 2 1	4 3 2 1
Gilles A Salles, MD, PhD	4 3 2 1	4 3 2 1
Editor	**Knowledge of subject matter**	**Effectiveness as an educator**
Neil Love, MD	4 3 2 1	4 3 2 1

REQUEST FOR CREDIT — Please print clearly

Name: . . . . . Specialty: . . . . .

Professional Designation:

☐ MD ☐ DO ☐ PharmD ☐ NP ☐ RN ☐ PA ☐ Other: . . . . .

Street Address: . . . . . Box/Suite: . . . . .

City, State, Zip: . . . . .

Telephone: . . . . . Fax: . . . . .

Email: . . . . .

Research To Practice designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: . . . . . Date: . . . . .

☐ **I would like Research To Practice to submit my CME credits to the ABIM to count toward my MOC points. I understand that because I am requesting MOC credit, Research To Practice will be required to share personally identifiable information with the ACCME and ABIM.**

Additional information for MOC credit (required):

Date of Birth (Month and Day Only): __ __ / __ __ ABIM 6-Digit ID Number: . . . . .

If you are not sure of your ABIM ID, please visit http://www.abim.org/verify-physician.aspx.

QID 2126

The expiration date for this activity is February 2020. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/FLUpdate119/CME.

Follicular Lymphoma™ UPDATE

PRSRT STD
U.S. POSTAGE
PAID
MIAMI, FL
PERMIT #1317

Neil Love, MD
Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

This activity is supported by educational grants from
Bayer HealthCare Pharmaceuticals, Celgene Corporation
and Gilead Sciences Inc.

Research
To Practice®

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Release date: February 2019
Expiration date: February 2020
Estimated time to complete: 2.25 hours